FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025183952> ?p ?o ?g. }

• W2025183952 endingPage "1011" @default.
• W2025183952 startingPage "1007" @default.
• W2025183952 abstract "Excessive adverse events were encountered in a Phase I/II study of cyclophosphamide (CY) dose deescalation in a fludarabine-based conditioning regimen for bone marrow transplantation from unrelated donors in patients with severe aplastic anemia. All patients received fixed doses of antithymocyte globulin, fludarabine, and low-dose total body irradiation. The starting CY dose was 150 mg/kg, with deescalation to 100 mg/kg, 50 mg/kg, or 0 mg/kg. CY dose level 0 mg/kg was closed due to graft failure in 3 of 3 patients. CY dose level 150 mg/kg was closed due to excessive organ toxicity (n = 6) or viral pneumonia (n = 1), resulting in the death of 7 of 14 patients. CY dose levels 50 and 100 mg/kg remain open. Thus, CY at doses of 150 mg/kg in combination with total body irradiation (2 Gy), fludarabine (120 mg/m2), and antithymocyte globulin was associated with excessive organ toxicity. Excessive adverse events were encountered in a Phase I/II study of cyclophosphamide (CY) dose deescalation in a fludarabine-based conditioning regimen for bone marrow transplantation from unrelated donors in patients with severe aplastic anemia. All patients received fixed doses of antithymocyte globulin, fludarabine, and low-dose total body irradiation. The starting CY dose was 150 mg/kg, with deescalation to 100 mg/kg, 50 mg/kg, or 0 mg/kg. CY dose level 0 mg/kg was closed due to graft failure in 3 of 3 patients. CY dose level 150 mg/kg was closed due to excessive organ toxicity (n = 6) or viral pneumonia (n = 1), resulting in the death of 7 of 14 patients. CY dose levels 50 and 100 mg/kg remain open. Thus, CY at doses of 150 mg/kg in combination with total body irradiation (2 Gy), fludarabine (120 mg/m2), and antithymocyte globulin was associated with excessive organ toxicity." @default.
• W2025183952 created "2016-06-24" @default.
• W2025183952 creator A5000560721 @default.
• W2025183952 creator A5001486008 @default.
• W2025183952 creator A5002479426 @default.
• W2025183952 creator A5006173110 @default.
• W2025183952 creator A5010962133 @default.
• W2025183952 creator A5011838093 @default.
• W2025183952 creator A5018922885 @default.
• W2025183952 creator A5035553129 @default.
• W2025183952 creator A5036425755 @default.
• W2025183952 creator A5040662951 @default.
• W2025183952 creator A5041346359 @default.
• W2025183952 creator A5054037976 @default.
• W2025183952 creator A5060519108 @default.
• W2025183952 creator A5074398879 @default.
• W2025183952 creator A5079204881 @default.
• W2025183952 creator A5083279961 @default.
• W2025183952 creator A5086494836 @default.
• W2025183952 creator A5091433944 @default.
• W2025183952 date "2012-07-01" @default.
• W2025183952 modified "2023-10-16" @default.
• W2025183952 title "Fludarabine-Based Conditioning for Marrow Transplantation from Unrelated Donors in Severe Aplastic Anemia: Early Results of a Cyclophosphamide Dose Deescalation Study Show Life-Threatening Adverse Events at Predefined Cyclophosphamide Dose Levels" @default.
• W2025183952 cites W2016294085 @default.
• W2025183952 cites W2018678214 @default.
• W2025183952 cites W2025909464 @default.
• W2025183952 cites W2037339859 @default.
• W2025183952 cites W2038332193 @default.
• W2025183952 cites W2056235669 @default.
• W2025183952 cites W2106456757 @default.
• W2025183952 cites W2109230263 @default.
• W2025183952 cites W2119566322 @default.
• W2025183952 cites W2129219275 @default.
• W2025183952 cites W2135819411 @default.
• W2025183952 cites W2149753414 @default.
• W2025183952 cites W2164126075 @default.
• W2025183952 cites W2171228629 @default.
• W2025183952 doi "https://doi.org/10.1016/j.bbmt.2012.04.014" @default.
• W2025183952 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3677744" @default.
• W2025183952 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22546497" @default.
• W2025183952 hasPublicationYear "2012" @default.
• W2025183952 type Work @default.
• W2025183952 sameAs 2025183952 @default.
• W2025183952 citedByCount "45" @default.
• W2025183952 countsByYear W20251839522012 @default.
• W2025183952 countsByYear W20251839522013 @default.
• W2025183952 countsByYear W20251839522014 @default.
• W2025183952 countsByYear W20251839522015 @default.
• W2025183952 countsByYear W20251839522016 @default.
• W2025183952 countsByYear W20251839522017 @default.
• W2025183952 countsByYear W20251839522018 @default.
• W2025183952 countsByYear W20251839522019 @default.
• W2025183952 countsByYear W20251839522020 @default.
• W2025183952 countsByYear W20251839522021 @default.
• W2025183952 countsByYear W20251839522023 @default.
• W2025183952 crossrefType "journal-article" @default.
• W2025183952 hasAuthorship W2025183952A5000560721 @default.
• W2025183952 hasAuthorship W2025183952A5001486008 @default.
• W2025183952 hasAuthorship W2025183952A5002479426 @default.
• W2025183952 hasAuthorship W2025183952A5006173110 @default.
• W2025183952 hasAuthorship W2025183952A5010962133 @default.
• W2025183952 hasAuthorship W2025183952A5011838093 @default.
• W2025183952 hasAuthorship W2025183952A5018922885 @default.
• W2025183952 hasAuthorship W2025183952A5035553129 @default.
• W2025183952 hasAuthorship W2025183952A5036425755 @default.
• W2025183952 hasAuthorship W2025183952A5040662951 @default.
• W2025183952 hasAuthorship W2025183952A5041346359 @default.
• W2025183952 hasAuthorship W2025183952A5054037976 @default.
• W2025183952 hasAuthorship W2025183952A5060519108 @default.
• W2025183952 hasAuthorship W2025183952A5074398879 @default.
• W2025183952 hasAuthorship W2025183952A5079204881 @default.
• W2025183952 hasAuthorship W2025183952A5083279961 @default.
• W2025183952 hasAuthorship W2025183952A5086494836 @default.
• W2025183952 hasAuthorship W2025183952A5091433944 @default.
• W2025183952 hasBestOaLocation W20251839521 @default.
• W2025183952 hasConcept C126322002 @default.
• W2025183952 hasConcept C141071460 @default.
• W2025183952 hasConcept C197934379 @default.
• W2025183952 hasConcept C2776694085 @default.
• W2025183952 hasConcept C2776755627 @default.
• W2025183952 hasConcept C2778248108 @default.
• W2025183952 hasConcept C2778880498 @default.
• W2025183952 hasConcept C2779263901 @default.
• W2025183952 hasConcept C2780007613 @default.
• W2025183952 hasConcept C2781413609 @default.
• W2025183952 hasConcept C2781440808 @default.
• W2025183952 hasConcept C2911091166 @default.
• W2025183952 hasConcept C29730261 @default.
• W2025183952 hasConcept C71924100 @default.
• W2025183952 hasConcept C90924648 @default.
• W2025183952 hasConceptScore W2025183952C126322002 @default.
• W2025183952 hasConceptScore W2025183952C141071460 @default.
• W2025183952 hasConceptScore W2025183952C197934379 @default.
• W2025183952 hasConceptScore W2025183952C2776694085 @default.
• W2025183952 hasConceptScore W2025183952C2776755627 @default.
• W2025183952 hasConceptScore W2025183952C2778248108 @default.
• W2025183952 hasConceptScore W2025183952C2778880498 @default.
• W2025183952 hasConceptScore W2025183952C2779263901 @default.

• next